On the stock market since 2013, it operates in the world of health and science. It has 79 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 55% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 24% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
A loss of $88.4M against $212K in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Over the last 12 months, executives reported 122 sells against just 12 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, CMRX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CMRX is a small company that closed last year at a loss. The road back to profit runs through spending discipline.